Leerink raised the firm’s price target on AnaptysBio (ANAB) to $85 from $66 and keeps an Outperform rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- GSK’s TESARO provides update on AnaptysBio litigation
- Joseph Thome Reiterates Buy on AnaptysBio as Royalty-Focused Model and Jemperli Legal Win Support $75 Price Target
- Delaware court dismisses Tesaro breach of contract claim against AnaptysBio
- First Tracks Biotherapeutics initiated with an Outperform at Leerink
- AnaptysBio price target lowered to $60 from $90 at UBS